Dynavax Technologies Corporation (DVAX) Reaches New 12-Month High at $18.10

Dynavax Technologies Corporation (NASDAQ:DVAX) shares hit a new 52-week high on Monday . The stock traded as high as $18.10 and last traded at $18.16, with a volume of 3,326,301 shares. The stock had previously closed at $16.55.

Several research analysts have weighed in on the stock. Cowen and Company reissued an “outperform” rating and set a $30.00 price objective on shares of Dynavax Technologies Corporation in a report on Thursday, August 10th. William Blair restated an “outperform” rating and issued a $30.00 price target on shares of Dynavax Technologies Corporation in a research report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. BidaskClub downgraded shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, J P Morgan Chase & Co upgraded shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $6.00 to $27.00 in a research report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Dynavax Technologies Corporation has a consensus rating of “Hold” and an average price target of $23.34.

The firm’s 50 day moving average is $12.61 and its 200 day moving average is $7.57. The stock’s market cap is $886.90 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.09. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.15 million. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. During the same period in the prior year, the company posted ($0.75) EPS. Analysts predict that Dynavax Technologies Corporation will post ($1.58) earnings per share for the current year.

Hedge funds have recently bought and sold shares of the company. GMT Capital Corp boosted its position in shares of Dynavax Technologies Corporation by 28.2% in the second quarter. GMT Capital Corp now owns 3,005,137 shares of the biopharmaceutical company’s stock valued at $29,450,000 after buying an additional 660,637 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Dynavax Technologies Corporation by 10.9% in the second quarter. Vanguard Group Inc. now owns 2,024,666 shares of the biopharmaceutical company’s stock valued at $19,538,000 after buying an additional 199,004 shares in the last quarter. PointState Capital LP purchased a new position in Dynavax Technologies Corporation during the second quarter valued at $13,510,000. Blair William & Co. IL boosted its position in Dynavax Technologies Corporation by 1.8% in the first quarter. Blair William & Co. IL now owns 1,346,494 shares of the biopharmaceutical company’s stock valued at $6,059,000 after buying an additional 23,701 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS increased its stake in shares of Dynavax Technologies Corporation by 4.0% in the second quarter. Kornitzer Capital Management Inc. KS now owns 1,142,360 shares of the biopharmaceutical company’s stock valued at $11,024,000 after buying an additional 43,850 shares in the last quarter. 57.49% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Dynavax Technologies Corporation (DVAX) Reaches New 12-Month High at $18.10” was reported by BNB Daily and is owned by of BNB Daily. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/dynavax-technologies-corporation-dvax-sets-new-12-month-high-at-18-10-updated.html.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply